Insitro
Machine learning-driven drug discovery platform founded by Stanford ML pioneer Daphne Koller
Biotech
📍 South San Francisco, CA
Founded 2018
Current Valuation
$2.4B
as of 2021-Q1
UNICORN
Insitro applies machine learning to generate and analyze human disease models, identifying drug targets that traditional pharma misses. Founded by Daphne Koller (Coursera co-founder, ex-Stanford CS / Calico chief computing officer). Pipeline partnerships with BMS and Gilead worth $2B+ in milestones. CPP Investment Board-led Series C valued the company at $2.4B in 2021.
Company Profile
HQ
South San Francisco, CA
Growth
Pre-revenue (collaboration milestones)
Last Round
Series C — $400M (Mar 2021) · Lead: Canada Pension Plan Investment Board
IPO Status
no imminent plans
Founders & Key People
Daphne Koller
Investors
Canada Pension Plan Investment Board · Andreessen Horowitz · ARCH Venture Partners · Foresite Capital · GV · T. Rowe Price · Bezos Expeditions · Casdin Capital
Products
- Insitro Human (in vitro disease models)
- Insitro ML platform
- Therapeutic pipeline (NAFLD, ALS, neuro)
Competitors
Recursion Pharmaceuticals · Isomorphic Labs · Atomic AI · Xaira Therapeutics · Generate Biomedicines
BiotechAI Drug DiscoveryMachine Learning
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2021-Q1. Refreshed quarterly.